CD79B Antibody (AT105-1): sc-59114

CD79B Antibody (AT105-1) is a mouse monoclonal IgG1 antibody that detects CD79B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). CD79B, also known as B29, is a critical component of the B cell antigen receptor complex, functioning alongside CD79A to facilitate the signaling necessary for B cell activation and development. CD79B (AT105-1) antibody enables research into CD79B′s essential role in surface expression of immunoglobulins, such as IgM and IgD, which are vital for antigen recognition and presentation. The cytoplasmic tail of CD79B contains an immuno-receptor tyrosine-based activation motif (ITAM) that is crucial for initiating downstream signaling cascades upon antigen binding, thereby activating tyrosine kinases that propagate the signal within the B cell. This signaling is fundamental for B cell proliferation, differentiation, and the generation of an effective immune response, making CD79B a significant target for research in immunology and potential therapeutic interventions in B cell-related disorders. Anti-CD79B antibody (AT105-1) serves as an invaluable tool for studying B cell biology and the mechanisms underlying immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (AT105-1) References:

1. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.  |  Garcia Vela, J., et al. 1999. Leukemia. 13: 1501-5. PMID: 10516749
2. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.  |  Nakamura, T., et al. 2016. Neuropathol Appl Neurobiol. 42: 279-90. PMID: 26111727
3. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.  |  Ormhøj, M., et al. 2019. Clin Cancer Res. 25: 7046-7057. PMID: 31439577
4. Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.  |  Herrera, AF., et al. 2022. Clin Cancer Res. 28: 1294-1301. PMID: 34980599
5. PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.  |  Zhou, J., et al. 2022. Front Oncol. 12: 824632. PMID: 35223507
6. Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.  |  Wang, W., et al. 2022. Ann Hematol. 101: 1869-1872. PMID: 35484253
7. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.  |  Yadav, R., et al. 2022. Pharmaceutics. 14: PMID: 35631556
8. Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.  |  Lenk, L., et al. 2022. Hemasphere. 6: e754. PMID: 35935606
9. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.  |  Wang, J., et al. 2023. Cancer Immunol Immunother. 72: 493-507. PMID: 35963895
10. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.  |  Seon, BK., et al. 2024. Leuk Res. 136: 107436. PMID: 38232613

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.